Targeting the MTA 1s-LM04 Pathway in Hormone Resistance
Final rept. 15 JUl 2004-14 Jul 2005
M D ANDERSON CANCER CENTER HOUSTON TX
Pagination or Media Count:
The overall goal of this research is to determine the role of LMO4 in breast cancer progression. New insight into these concepts will likely provide new targets and strategies for therapeutic intervention. We have identified estrogen receptor alpha ER and its corepressors MTA1 and MTA1s as novel binding partners of LMO4 and have shown that LMO4 is essential to maintain ER transcriptional repression in breast cancer cells. This work was reported in a recent Cancer Research article. Since LMO4 is up regulated in human breast cancers, repression of alpha ER transactivation functions by LMO4 might contribute to the process of breast cancer progression by allowing the development of ERa-negative phenotypes and hormone resistance, leading to increased aggressiveness of breast cancer cells.
- Medicine and Medical Research